• 03/13/2024, Sophia Antipolis, France

    Median Technologies meets the eligibility conditionsfor the PEA-PME scheme

    Median Technologies confirms its eligibility for the PEA-PME scheme.
    Read more Download 202409313_PR_PEAPME_EN.pdf
  • 03/08/2024, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of February 29th, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of February 29th, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20240308_PR_shares_votingrights_Feb2024.pdf
  • 02/29/2024, Sophia Antipolis, France

    Median Technologies to participate in the TD Cowen’s 44th Annual Health Care Conference

    Median Technologies will be participating in the TD Cowen’s 44th Annual Health Care Conference, taking place on March 4 – 6 ,2024, in Boston, MA, USA. Fredrik Brag, Median’s CEO and Founder will present on March 6th at 2:50-3:20 pm ET (8:50 pm CET).
    Read more Download 20240229_PR_COWEN2024_EN.pdf
  • 02/26/2024, Sophia Antipolis, France

    Median Technologies to participate and speak at the 2024 European Congress of Radiology (ECR), February 28 – March 3, Vienna, Austria

    Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces today that the Company will be participating and speaking at the premier European radiology conference, the European Congress of Radiology (ECR), being held in Vienna, Austria, February 28 – March 3, 2024. 
    Read more Download 20240226_PR_ECR2024_EN.pdf
  • 02/08/2024, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of January 31st, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of January 31st, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20240208_PR_shares_votingrights_Jan2024.pdf
  • 01/29/2024, Sophia Antipolis, France

    Median Technologies reports 2023 revenue and summarizes 2024 strategic outlook.

    Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.
    Read more Download 20240129_PR_Toplines_EN_final.pdf
  • 01/26/2024,

    New date for Median Technologies’ webcasts:February 1st, 2024

     Median Technologies announces that Fredrik Brag, CEO and Founder of Median Technologies, will provide a company update on February 1, 2024
    Read more Download 20240126_PR_NewWebcast_EN.pdf
  • 01/25/2024, Sophia Antipolis, France

    Median Technologies to host two webcasts, and provide a company update on January 30, 2024

    Median Technologies announced today that Fredrik Brag, CEO and Founder of Median Technologies, will provide a company update on January 30, 2024
    Read more Download 20240125_PR_Webcast_EN.pdf
  • 01/22/2024, Sophia Antipolis, France

    Financial Communications Schedule for the First Half of 2024

    Press release – For immediate release – 5:45 pm CET Financial Communications Schedule for the First Half of 2024 Median Technologies (FR0011049824, ALMDT, PEA/SME eligible), announces the publication date for its 2023 results: Publication Date 2023 Results April 25, 2024Distribution after the close of trading
    Read more Download 20240122_PR_FiComS12024_EN.pdf
  • 01/17/2024, Sophia Antipolis, France

    Median Technologies Reports Excellent Results from Its Independent Verification Study

    In an important milestone towards market introduction, Median Technologies announces that its CADe/CADx Software as Medical Device (SaMD), eyonis™ LCS, has demonstrated excellent performance in an independent verification study—a critical step in the regulatory process for obtaining 510(k) clearance and CE marking.
    Read more Download 20240117_PR_eyonis_EN_final.pdf